Home › Research › Tau biomarkers
Chi3l1/YKL-40 is controlled by the astrocyte circadian clock and regulates neuroinflammation and Alzheimer's disease pathogenesis
Lananna BV, McKee CA, King MW, Del-Aguila JL, Dimitry JM, Farias FHG, Nadarajah CJ, Xiong DD et al.. Science translational medicine, 2020-12-01
Topic: Brain proteins, microglia and lab models
Plain-language summary
Regulation of glial activation and neuroinflammation are critical factors in the pathogenesis of Alzheimer's disease (AD). YKL-40, a primarily astrocytic protein encoded by the gene Chi3l1 , is a widely studied cerebrospinal fluid biomarker that increases with aging and early in AD. However, the function of Chi3l1 /YKL-40 in AD is unknown.
What this study adds
Evidence grade: Moderate
YKL-40 is a widely studied spinal-fluid marker that rises with aging and early in Alzheimer's, but what it does was unknown. In a cohort of people with Alzheimer's, this study found that a *CHI3L1* gene variant that lowers spinal-fluid YKL-40 was associated with slower progression; in mice, removing the gene had no effect on astrocyte activation and modestly increased microglial activation at baseline.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Lananna, B. V., McKee, C. A., King, M. W., Del-Aguila, J. L., Dimitry, J. M., Farias, F. H. G., et al. (2020). Chi3l1/YKL-40 is controlled by the astrocyte circadian clock and regulates neuroinflammation and Alzheimer's disease pathogenesis. Science translational medicine. https://doi.org/10.1126/scitranslmed.aax3519
Vancouver
Lananna BV, McKee CA, King MW, Del-Aguila JL, Dimitry JM, Farias FHG, et al. Chi3l1/YKL-40 is controlled by the astrocyte circadian clock and regulates neuroinflammation and Alzheimer's disease pathogenesis. Science translational medicine. 2020. doi:10.1126/scitranslmed.aax3519. PMID: 33328329.
BibTeX
@article{lananna2020-33328329,
author = {Lananna, B. V. and McKee, C. A. and King, M. W. and Del-Aguila, J. L. and Dimitry, J. M. and Farias, F. H. G. and Nadarajah, C. J. and Xiong, D. D. and others},
title = {{Chi3l1/YKL-40 is controlled by the astrocyte circadian clock and regulates neuroinflammation and Alzheimer's disease pathogenesis}},
journal = {Science translational medicine},
year = {2020},
doi = {10.1126/scitranslmed.aax3519},
pmid = {33328329},
url = {https://doi.org/10.1126/scitranslmed.aax3519}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- YKL-40, a primarily astrocytic protein encoded by the gene Chi3l1 , is a widely studied cerebrospinal fluid biomarker that increases with aging and early in AD.
- However, the function of Chi3l1 /YKL-40 in AD is unknown.
- In a cohort of patients with AD, we observed that a variant in the human CHI3L1 gene, which results in decreased CSF YKL-40 expression, was associated with slower AD progression.
- At baseline, Chi3l1 deletion in mice had no effect on astrocyte activation while modestly promoting microglial activation.
Why it matters
YKL-40 is a widely studied spinal-fluid marker that rises with aging and early in Alzheimer's, but what it does was unknown. In a cohort of people with Alzheimer's, this study found that a *CHI3L1* gene variant that lowers spinal-fluid YKL-40 was associated with slower progression; in mice, removing the gene had no effect on astrocyte activation and modestly increased microglial activation at baseline. The human result is an association and the mouse work is early laboratory research, so it does not show that lowering YKL-40 treats or prevents Alzheimer's.
New to this subject? Start with our plain-English guide: Blood tests & biomarkers →
Study details
- Evidence strengthModerate
How this study scored 50/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Science translational medicine) |
| Journal's citation record | 3 / 4 | Science Translational Medicine: journal h-index 365 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 2 / 5 | 2020 — within 10 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 5 / 7 | Cited 203 times (OpenAlex, 2026-10-10) |
| Citations per year | 4 / 5 | 25.4 citations a year over 8 year(s) since 2020 |
| Impact for its field and year | 3 / 6 | Cited 7.9× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 2 / 6 | Cited by 8 other studies in this library |
| Still being cited | 3 / 4 | Cited 106 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 2 / 4 | Last-listed author Erik S. Musiek: h-index 46 (OpenAlex, whole career) |
| Institution's track record | 2 / 3 | Washington University in St. Louis: institution h-index 1,962 (OpenAlex) |
| Multicenter collaboration | 2 / 3 | OpenAlex lists 4 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 33328329) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 50 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1126/scitranslmed.aax3519
- PubMed: 33328329
- Original source →
- Free full text: PubMed Central →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Later studies that cite this one
8 studies in the alzhub library list this one in their references.
Related studies in Tau biomarkers from nearby years
Also tagged “tdp-43”
1,150 studies in the library carry the topic tag “tdp-43”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,150 tagged studies.